PMID: 10455147

Loo TW, Clarke DM
The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface.
J Biol Chem. 1999 Aug 27;274(35):24759-65., 1999-08-27 [PubMed]
Sentences
No. Mutations Sentence Comment
29 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:29:106
status: NEW
view ABCB1 p.Pro709Gly details
EXPERIMENTAL PROCEDURES Generation of Deletion Mutants-The cDNAs coding for full-length MDR1 (36), mutant P709G (37), or the N-half and C-half P-gp molecules (14) and containing the epitope for monoclonal antibody A52 at the C-terminal ends were subcloned into the mammalian expression vector pMT21. Login to comment
43 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:43:103
status: NEW
view ABCB1 p.Pro709Gly details
For expression studies involving drug resistance assays, the cDNAs of the A52-tagged wild-type, mutant P709G, N-half, C-half, and TMD1ϩ2 were also inserted into the Epstein-Barr virus-based vector, pREP4 (Invitrogen Inc.). Login to comment
137 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:137:57
status: NEW
view ABCB1 p.Pro709Gly details
The cDNAs for the A52-tagged wild-type, and P-gp mutants P709G, N-half, C-half, and TMD1ϩ2 were inserted into the pREP4 vector and transfected into HEK 293(EBNA-1) cells. Login to comment
138 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:138:7
status: NEW
view ABCB1 p.Pro709Gly details
Mutant P709G was included because it shows similar processing defects as mutant TMD1ϩ2. Login to comment
139 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:139:12
status: NEW
view ABCB1 p.Pro709Gly details
When mutant P709G is expressed in HEK 293 cells in the absence of drug substrate, the major product is a protein of 150 kDa that is retained in the endoplasmic reticulum as a core-glycosylated intermediate (37). Login to comment
145 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:145:11
status: NEW
view ABCB1 p.Pro709Gly details
For mutant P709G, the major product in the absence of drug substrate was the 150-kDa (core-glycosylated) protein, while the 170-kDa protein was the major product in the presence of substrate. When N-half (90-kDa) P-gp was co-expressed with C-half P-gp in the presence of substrate, another N-half protein of 115 kDa was present. Login to comment
155 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:155:57
status: NEW
view ABCB1 p.Pro709Gly details
Fig. 6A shows that the mature forms of wild-type, mutant P709G, N-half, and TMD1ϩ2 P-gps were still present in the cells after treatment with cyclosporin A followed by vinblastine. Login to comment
170 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:170:10
status: NEW
view ABCB1 p.Pro709Gly details
In mutant P709G or in the half-molecules of P-gp, preincubation of the cells with cyclosporin A greatly increased the relative resistance to vinblastine. Login to comment
171 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:171:28
status: NEW
view ABCB1 p.Pro709Gly details
The cells expressing mutant P709G that were not pretreated with cyclosporin A showed about an 8-fold increase in resistance to vinblastine relative to the control cells. Login to comment
195 ABCB1 p.Pro709Gly
X
ABCB1 p.Pro709Gly 10455147:195:153
status: NEW
view ABCB1 p.Pro709Gly details
A, HEK 293(EBNA-1) cells were transfected with pREP4 vector (B, Control) or pREP4 vectors containing cDNAs for full-length wild-type P-gp (Wild), mutant P709G, or TMD1ϩ2, or they were cotransfected with the cDNAs for the N-half and C-half of P-gp (Halves). Login to comment